Merck & Co., Inc. reported second-quarter 2026 results on August 4, 2026, reporting a GAAP loss per share of $0.54 and non-GAAP loss per share of $0.13, driven by a $2.31 per share charge for the acquisition of Terns Pharmaceuticals. Total worldwide sales reached $16.6 billion, representing 5% growth year-over-year, with KEYTRUDA/KEYTRUDA QLEX sales contributing $8.4 billion and WINREVAIR sales surging 75% to $588 million. The company narrowed and raised its full-year 2026 sales outlook to between $66.3 billion and $67.3 billion, while raising the expected non-GAAP EPS range to between $2.66 and $2.76. Merck operates in the pharmaceutical industry, developing and commercializing medicines, vaccines, and animal health products.